Navigation Links
StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals

LONDON, February 28, 2013 /PRNewswire/ --

Markets responded well to Fed chief Ben Bernanke's remarks about the stimulus policy. On the other hand, there are some worries about the ongoing Sequestration debate as well. However, broader indices remained in the green and The Dow Jones closed 1.26% higher at 14,075.37, the S&P 500 closed 1.27% higher at 1,515.99, and the NASDAQ closed 1.04% higher at 3,162.26. Our research team took a look at major drug makers stocks including companies like Eli Lilly & Co. (NYSE: LLY), Bristol Myers Squibb Co. (NYSE: BMY), Astex Pharmaceuticals Inc. (NASDAQ: ASTX) and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). StockCall has issued technical analysis and charting reports on LLY, BMY, ASTX and RPTP. Download these free reports now at

Eli Lilly & Co. is currently in a bullish mode as the stock created a new 52-week high price in its latest trading session. The stock closed the session at $54.80, up 0.68 percent. Eli Lilly traded in the range of $54.26 and $54.99 during the session. Its first support level is at $53.83 and upon breaching this level, the stock may go down to $52.46 level. On the upside, Eli Lilly & Co.'s stock may touch $57.44 level. The stock has traded in the range of $38.56 and $54.99 in the past 52 weeks and it grew by 40 percent during the same time period. On a Year-to-Date basis, the stock is up 11.11 percent. Download the free research on LLY today by registering at

Bristol Myers Squibb Co.'s shares also touched a new 52-week high in its latest trading session, ending the day 1.95 percent higher at $37.10. The stock fell to an intra-day low of $36.31, while its intra-day high stood at $37.22. With the upward movement, the stock grew more than 13 percent this year, compared to a gain of 6.3 percent for the S&P 500. The stock has strong support at around $37.03, as it shows a bullish trend. The stock is trading below than its 20-day and 50-day moving averages. Sign up and have access to our free report on BMY at

Astex Pharmaceuticals traded in the range of $3.08 and $3.24 in its latest trading session and ended it at $3.19, up 1.92 percent. The stock's 52 weeks range stands at $1.57 and $3.55. Astex Pharma. is up 62.76 percent in the past 12 months, while it gained 9 percent so far this year. The stock is in a bullish mode and may find its first support level at $3.17. It is trading below its 20-day moving average of $3.29 but above its 50-day average price of $3.14. Sign up and read the complimentary report on ASTX at

Shares of Raptor Pharma ended their previous trading session marginally lower at $4.98, down 0.40 percent. The stock lost more than 14 percent this year, in contrast to the broad market. The stock has slipped from $5.03 resistance level. It has support at around $4.87 at the moment. With its downward movement, Raptor is trading below its 20-day moving average price. The stock may touch $5.08 level in the coming trading sessions. The free report on RPTP can be downloaded by signing up now at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation
2. Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
3. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
4. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
5. Omnyx Share Their Insight on Agile Software Development for Medical Devices
6. Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
7. GlaxoSmithKline Share Their Insight on Understanding DDI With a View to Better Prediction and Control
8. Pro-Dex Provides Insight Into Fiscal 2013 Operating Plan And Preliminary Results For Fiscal 2012
9. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
10. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
11. New Survey Reveals How Patients Choose Their Pharmacy; AccentHealth Garners Consumer Insights from the Waiting Room
Post Your Comments:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):